Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
NHLBI Catalyze program supports early-stage medical device prototype optimization and translational research for heart, lung, blood, and sleep (HLBS) diseases.
Funder: National Institutes of Health
Due Dates: February 11, 2027 (Application) | June 17, 2027 (Application) | October 21, 2027 (Application) | December 23, 2027 (Closing date)
Funding Amounts: Up to $300,000 in direct costs per year for up to two years
Summary: NHLBI supports optimization of medical device prototypes, diagnostics, and research tools for heart, lung, blood, and sleep diseases.
Key Information: At least one Accelerator Partner and its support letter are required; clinical research and clinical trials are excluded.
Description
The National Heart, Lung, and Blood Institute (NHLBI) offers this R33 opportunity through its Catalyze Product Definition program. It supports early translational work on medical devices, diagnostics, and research tools addressing heart, lung, blood, and sleep (HLBS) diseases and disorders. Supported activities include prototype testing and design modification, diagnostic assay development, system integration, engineering optimization, and product performance characterization.
Projects should offer significant improvements over existing solutions, address unmet needs, and have a strong biological rationale supported by preliminary data. The goal is to prepare products for further preclinical optimization and characterization through the NHLBI Catalyze Preclinical program or independent federal or private support. The Catalyze Coordinating Center provides development guidance and milestone-driven project management support.
